Related studies have reported that B7-H3 may participate in the JAK/STAT and PI3K/Akt/mTOR pathways and that the inhibition of B7-H3 increases the response of tumor cells to inhibitors of these pathways [79,80]. Here, CD276 is linked to neoplasm.